(NASDAQ: INSM) Insmed's forecast annual revenue growth rate of 73.96% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Insmed's revenue in 2025 is $381,030,000.On average, 8 Wall Street analysts forecast INSM's revenue for 2025 to be $85,817,485,655, with the lowest INSM revenue forecast at $81,962,515,350, and the highest INSM revenue forecast at $88,692,548,555. On average, 8 Wall Street analysts forecast INSM's revenue for 2026 to be $189,112,293,806, with the lowest INSM revenue forecast at $161,169,268,795, and the highest INSM revenue forecast at $213,290,143,001.
In 2027, INSM is forecast to generate $379,953,085,991 in revenue, with the lowest revenue forecast at $315,173,192,359 and the highest revenue forecast at $455,711,585,346.